Edition:
United Kingdom

Getinge AB (GETIb.ST)

GETIb.ST on Stockholm Stock Exchange

116.50SEK
18 Apr 2019
Change (% chg)

1.15kr (+1.00%)
Prev Close
115.35kr
Open
114.80kr
Day's High
116.50kr
Day's Low
114.30kr
Volume
777,515
Avg. Vol
1,166,680
52-wk High
117.70kr
52-wk Low
74.74kr

Latest Key Developments (Source: Significant Developments)

Hanza Expands Cooperation With Getinge
Monday, 8 Apr 2019 

April 8 (Reuters) - Hanza AB ::EXPANDS COOPERATION WITH GETINGE.NEW DEAL HAS YEARLY VALUE OF ABOUT SEK 20 MILLION.PRODUCTION TO START IMMEDIATELY AND TO BE FULLY OPERATIONAL IN LAST QUARTER OF 2019.  Full Article

Getinge says Johan Malmquist proposed as new chairman of board
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Getinge AB ::JOHAN MALMQUIST PROPOSED AS NEW CHAIRMAN OF BOARD FOR GETINGE AB.CARL BENNET WILL CONTINUE AS MEMBER OF BOARD AND IS PROPOSED AS VICE CHAIRMAN OF BOARD.  Full Article

Getinge issues voluntary medical device recall for the QUADROX‐i Neonatal Oxygenator
Monday, 26 Nov 2018 

Nov 26 (Reuters) - Getinge AB ::INFORMS ABOUT VOLUNTARY RECALL OF QUADROX-I NEONATAL OXYGENATOR.SAYS HAS REPORTED TO RELEVANT COMPETENT AUTHORITIES ACCORDING TO APPLICABLE REGULATIONS AND DOES NOT EXPECT THE COST FOR THE RECALL TO BE MATERIAL.SAYS TO DATE, THERE ARE NO KNOWN ADVERSE EVENTS ASSOCIATED WITH SERIOUS INJURY OR DEATH.SAYS THE RECALL CONCERNS AN ENCLOSED ADAPTER TO THE DEVICE, WHICH CAN CAUSE BLOOD LEAKAGE AT THE BLOOD INLET CONNECTOR.SAYS IN TOTAL 22,749 UNITS OF QUADROX-I NEONATAL HAVE BEEN DISTRIBUTED GLOBALLY BETWEEN OCTOBER, 2016 AND OCTOBER 2018. THE ADAPTER IS USED IN 10% OF THE THERAPY CASES. IN THE US, THE RECALL AFFECTS 9 CUSTOMERS, AND HAS BEEN CLASSIFIED AS A CLASS I RECALL BY THE FDA.SAYS SINCE DECEMBER 2017 THE PRODUCT IS NO LONGER DISTRIBUTED TO THE US MARKET .  Full Article

Getinge Makes 350 Mln SEK Additional Provisions
Wednesday, 21 Mar 2018 

March 21 (Reuters) - Getinge ::MAKES ADDITIONAL PROVISIONS OF 350 MILLION SWEDISH CROWNS ($42.63 MILLION) IN RELATION TO BRAZILIAN INVESTIGATIONS.SAYS ‍TO MAKE AN ADDITIONAL PROVISON OF MSEK 350 RELATED TO, AMONG OTHER THINGS, ALLEGED FRAUD IN BIDDING PROCEEDINGS IN BRAZIL MAINLY ATTRIBUTABLE TO YEARS 2004-2015​.SAYS ‍ADDITIONAL PROVISION WILL HAVE EFFECT ON OPERATING PROFIT OF Q1 2018​.SAYS ‍NEGOTIATIONS WILL CONTINUE WITH RELEVANT AUTHORITIES AND ARE EXPECTED TO BE FINALIZED DURING 2018​.SAYS ‍IT CANNOT BE EXCLUDED THAT SETTLEMENTS WITH RELEVANT AUTHORITIES WILL HAVE ADDITIONAL SIGNIFICANT EFFECT ON RESULT AND FINANCIAL POSITION OF GETINGE​.SAYS PROVISIONS ‍PRIMARILY RELATED TO GETINGE'S BRAZILIAN SUBSIDIARIES MAQUET CARDIOPULMONARY DO BRASIL INDÚSTRIA E COMÉRCIO LTDA AND MAQUET DO BRASIL EQUIPAMENTOS MÉDICOS LTDA​.  Full Article

Getinge Q4 core profit far below forecast​
Monday, 29 Jan 2018 

Jan 29 (Reuters) - Getinge ::Q4 ‍ORDER INTAKE INCREASED BY 2.3% TO SEK 6,624 M (6,473)​.Q4 ‍ORDER INTAKE INCREASED ORGANICALLY BY 6.6%​.Q4 ‍NET SALES FELL BY 0.8% TO SEK 7,371 M (7,434)​.Q4 ‍EBITA 1** AMOUNTED TO SEK 1,111 M (1,689) WITH AN EBITA 1 MARGIN OF 15.1% (22.7)​.Q4 ‍EXCLUDING NON-RECURRING ITEMS, EBITA 1 AMOUNTED TO SEK 1,377 M (1,484) AND EBITA 1 MARGIN TO 18.7% (20.0)​.SAYS ‍A DIVIDEND PER SHARE OF SEK 1.50 (1.75***) IS PROPOSED, CORRESPONDING TO SEK 409 M (477).REUTERS POLL: GETINGE Q4 ORDER INTAKE WAS SEEN AT 6.5 BILLION SEK, ADJUSTED. EBITA AT 1.6 BILLION, DIVIDEND AT 1.76 SEK/SHARE​.OUTLOOK 2018: ORGANIC SALES GROWTH IS EXPECTED TO BE SLIGHTLY POSITIVE IN 2018​.OUTLOOK 2018: CURRENCY TRANSACTION EFFECTS ARE EXPECTED TO HAVE A NEGATIVE IMPACT OF APPROXIMATELY SEK 100 M ON THE GROUP’S 2018 EBIT.SAYS EXCLUDING NON-RECURRING ITEMS, GROSS PROFIT WAS IN LINE WITH THE YEAR-EARLIER PERIOD, WHILE EBITA 1 WAS NOT SATISFACTORY.OPERATING PROFIT WAS NEGATIVELY AFFECTED BY OUTSTANDING GROUP-WIDE EXPENSES FOLLOWING THE DISTRIBUTION OF ARJO.SAYS WE ARE TACKLING THIS BY GRADUALLY REDUCING OUR OPERATING EXPENSES IN RELATION TO SALES.SAYS NON-RECURRING COSTS CHARGED TO GROSS PROFIT FOR THE QUARTER PRIMARILY COMPRISE WRITE-DOWNS OF A NUMBER OF CAPITALIZED RESEARCH PROJECTS AND INVENTORY IMPAIRMENT. ​.SAYS THE REMEDIATION PROGRAM RELATED TO THE CONSENT DECREE WITH FDA CONTINUED ACCORDING TO PLAN AT ALL UNITS CONCERNED DURING THE FOURTH QUARTER.  Full Article

Getinge sets new financial targets after distribution of Arjo
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Getinge :Revised strategy, new financial targets and restated financial information for Getinge (excluding Arjo).Says ‍focus is on organic growth and Getinge foresees an organic market growth of 2-4% on average during 2017-2020 in addressable market​.Says ‍Getinge's organic growth in net sales is expected to increase gradually during 2018 and move closer to expected market growth on a run-rate basis by end of 2018​.Says targets ‍average growth in organic net sales: 2-4%​.Says ‍targets average earnings per share growth: >10%​.Says ‍dividend policy: 30-50% of net income.Getinge is distributing the Patient & Post-Acute Care business area​ into a separately listed company called Arjo.Says Arjo's shares of series B will be listed on Nasdaq Stockholm on December 12, 2017.  Full Article

Getinge Q3 core profit lags expectations, targets PPAC listing by year-end ​
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Getinge :Q3 ‍order intake increased by 2.2% to sek 7,334 m (7,176). Order intake increased organically by 4.7%.​.Getinge q3 - ‍net sales fell by 3.4% to sek 6,696 m (6,929). Net sales decreased organically by 0.7%.​.Q3 ‍ebita 1* declined by 31.6% to sek 659 m​.Getinge says organic sales growth is expected to be slightly positive in 2017.‍​.Getinge says currency transaction effects are expected to have a positive impact of approximately sek 250 m on getinge’s 2017 ebit‍​.Reuters poll: getinge q3 order intake was seen at 7.2 billion sek, adjusted. Ebita at 904 million.Says ‍net sales were adversely impacted by lower order intake in q2 and higher expenses partly related to work on preparing proposed distribution of patient & post-acute care business area​.Getinge says remainder of 2017 will be challenging, partly because the fourth quarter is our most important quarter in terms of sales and profitability, and partly because we have large-scale projects to complete before the start of 2018‍​.Getinge says aim is to distribute and list ppac division before end of year, on condition of a decision by the board and the approval of an extraordinary general meeting‍​.  Full Article

Getinge sees 2017 organic growth in lower half of 0-2 pct guidance range - CEO
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Getinge Ab CEO Mattias Perjos in conference call with analysts and media: :says sees f/y 2017 organic sales growth in lower half of 0-2 percent guidance range.  Full Article

Getinge resolves on fully guaranteed 4 bln SEK rights issue
Friday, 18 Aug 2017 

Aug 18 (Reuters) - Getinge Ab :says today, the Board of Directors of Getinge AB, with authorization from the Extraordinary General Meeting on August 15, 2017, has resolved on a rights issue of MSEK 4,324 with the purpose to strengthen the group’s balance sheet by reducing leverage and thereby providing improved operational flexibility.says subscription price in rights issue is sek 127 per share.says main shareholder, carl bennet ab has undertaken to subscribe for its portion of rights issue and committed to subscribe for shares that are not subscribed for in rights issue.says fourth swedish national pension fund has expressed its intention to subscribe for its portion of rights issue.says rights issue will, if fully subscribed, increase getinge's share capital by sek 17,023,098, from current sek 119,161,688.50.Getinge announced plans for the rights issue on June 14 nL8N1JB2HV.  Full Article

Getinge to cooperate with Brazilian authorities on cartel probe
Thursday, 3 Aug 2017 

Aug 3 (Reuters) - Getinge AB :Getinge says to cooperate with Brazilian authorities on local ongoing investigations.Says it is currently presumed that outcome of ongoing investigations will not have a material financial impact on group.Says that at this early stage of the process impact cannot be excluded.Getinge says investigation is part of ongoing public investigations on cartel activities related to sales of medical equipment and is being carried out by Brazilian authorities.  Full Article

Medical gear group Getinge posts profit rise, shares soar

STOCKHOLM Troubled Swedish medical technology group Getinge reported an unexpected gain in fourth-quarter core profit on a stronger margin, and forecast an increase in sales in 2019, sending its shares soaring more than 12 percent.